Dec 12- A panel of experts advising the U.S. Food and Drug Administration said an oral drug made by Merck& Co was effective in treating grass pollen allergy but expressed concerns about the drug's safety in children. It is sold as Grazax in Europe by Merck's partner ALK Abello.» Read More
Pfizer stock is down 13% so far today on news that development of its Lipitor successor – torceptrapib – has been halted. Analysts have downgraded the stock and cut price targets as a result. Barbara Ryan – managing director and senior analyst at Deutsche Bank – disagrees though. She appeared on “Morning Call” to say that the dip in price today is a buy-in opportunity.